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OBJECTIVE — Phobic anxiety has been associated with increased risk of cardiovascular
disease (CVD), but the underlying mechanisms are poorly understood. We aimed to determine
whether associations of phobic anxiety with several known markers of CVD might be contrib-
utors.
RESEARCHDESIGNANDMETHODS — Weuseda16-pointvalidatedindex(Crown-
Crisp) measured in 1988 to categorize 984 women with type 2 diabetes from the Nurses’ Health
Study as having low, moderate, or high phobic anxiety. Groups were then compared for differ-
ences in adipokines (adiponectin and leptin), inﬂammatory markers (C-reactive protein and
tumor necrosis factor [TNF]- receptor II), and markers of endothelial function (sE-selectin,
soluble intercellular adhesion molecule [sICAM]-1) measured on blood samples provided be-
tween 1989 and 1990.
RESULTS — Higher levels of phobic anxiety were associated with higher BMI and lower
education. Higher levels of phobic anxiety were also associated with higher leptin and soluble
TNF-receptorIIinbothcrudeanalysesandafteradjustmentforpotentialconfounders.sICAM
andsE-selectinwerehigherinthehighesttertilecomparedwiththemiddletertile,buttherewas
no signiﬁcant trend across tertiles. We found no association between phobic anxiety and adi-
ponectin.
CONCLUSIONS — High levels of phobic anxiety are associated with increased levels of
leptin and inﬂammatory markers, which may in part explain the previously observed relation-
ship between anxiety and other psychosocial disorders with CVD.
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C
ardiovascular disease (CVD) is the
leading cause of death in women in
the U.S. and most of the developed
world. Despite advances in our under-
standing and treatment of several cardio-
vascular risk factors, a large proportion of
the CVD burden remains unexplained by
traditional risk factors. Moreover, among
women with diabetes, CVD mortality has
not improved in the last three decades,
despite improvements among diabetic
men (1). Psychosocial factors including
anxietyhavebeenproposedasriskfactors
for the development of CVD (2), and, un-
like most traditional risk factors, anxiety
is more common in women. Phobic anx-
iety in particular has been associated with
increased risk of death from CVD in sev-
eral prospective cohort studies in men
(3). In a large prospective cohort study in
women (4), increased phobic anxiety was
associated with increased risk of fatal cor-
onary heart disease and sudden cardiac
death.
The association between phobic anx-
iety and increased risk from coronary
heart disease is not completely explained
by established CVD risk factors (4), and
pathwaysinvolvingbehavioralfactors,in-
creased sympathetic tone (4), endothelial
dysfunction (5), dyslipidemia (6), and in-
creased inﬂammatory biomarkers (7)
have been proposed. Increased anxiety
may also have an impact on adipose tis-
sue, and several studies have linked psy-
chological factors with changes in body
fat distribution and the metabolic syn-
drome, possibly mediated through
changes in the sympathetic nervous sys-
tem (8). Despite the high prevalence of
anxiety in the general population, few
studies have focused on the relationship
between inﬂammatory biomarkers and
anxiety, and the relation of anxiety to cir-
culating leptin and adiponectin levels has
never been examined in a study large
enough to allow adjustment for possible
confounders. Therefore, to examine the
association between phobic anxiety, as
measured by the Crown-Crisp index
(CCI), adipokine levels, and inﬂamma-
tory biomarkers, we conducted a cohort
study in 984 women with diabetes. Our
objective was to determine whether high
phobic anxiety is associated with in-
creased levels of inﬂammatory biomark-
ers, markers of endothelial function and
leptinlevels,and/orwithloweradiponec-
tin levels in women with diabetes.
RESEARCH DESIGN AND
METHODS— The Nurses’ Health
Study began in 1976 with the enrollment
of 121,700 female nurses aged 30–55
years who received biennially mailed
questionnaires on lifestyle factors and
health outcomes. Blood samples were ob-
tained from 32,826 study participants
from 1989 to 1990. Among participants
who returned blood samples, 1,188
womenhadaconﬁrmeddiagnosisoftype
2 diabetes, which was validated as previ-
ously reported (9). The current analysis
includes 984 women with diabetes, for
whommeasuresofhormonesandinﬂam-
matory markers, as well as data to calcu-
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and who were free of coronary heart dis-
ease (myocardial infarction, coronary ar-
tery bypass grafting, or percutaneous
transluminal coronary angioplasty) and
stroke at blood draw in 1990.
Assessment of phobic anxiety
The Crown-Crisp phobic anxiety sub-
scalewascompletedbyparticipantsinthe
Nurses’ Health Study in 1988. The CCI
(also called the Middlesex Hospital Ques-
tionnaire) is a standardized, self-rating
questionnaire, and the phobic anxiety
subscale measures common symptoms of
phobic anxiety. It includes eight ques-
tions with two to three levels of possible
responses to each question, allowing
scores ranging from 0 to 16, with higher
scores given to higher levels of phobic
anxiety (10). The CCI has been validated
in psychiatric outpatient clinic settings
and found to discriminate patients with
anxiety disorders and agoraphobia from
healthy control subjects (10,11). The
mean score on the phobic anxiety sub-
scale in subjects with psychiatrist diag-
nosed anxiety disorder is 5.6 (11). The
internal validity of the phobic anxiety
subscale of the CCI in the Nurses’ Health
Study population has been tested previ-
ously where it was associated with use of
tranquilizer medications in 2000 (4). The
individual questions and response op-
tions have been reported previously (4).
Forthosewithmissingdataononeortwo
questions (n  59), the total score was
divided by the fraction of questions an-
swered and then rounded to the nearest
whole number consistent with previous
studies that have used the CCI (4). We
categorized the total score into the cate-
gories of 0 or 1, 2–3, and 4, or higher
(highest levels of phobic anxiety) based
on frequency distribution similar to pre-
vious reports (4). These categories also
separated the population into approxi-
mate tertiles.
Assessment of hormones and
inﬂammatory markers
Blood samples were drawn in 1989 or
1990. Participants were sent a blood-set
kit that included supplies and instruc-
tions. Participants arranged for the blood
to be drawn into tubes containing liquid
EDTA and sent the samples back by pre-
paid overnight courier. Most samples ar-
rived within 24 h of the blood draw. After
arrival in the laboratory, samples were
centrifuged and aliquotted into cryotubes
as plasma, buffy coat, and erythrocytes.
Cryotubes were stored in liquid-nitrogen
freezers at 130°C or lower.
Quantiﬁcation of biomarker levels in
the Nurses’ Health Study has been de-
scribed in detail previously (9). Adi-
ponectin and leptin were assayed using a
radioimmunoassay from Linco Research
(St. Charles, MO), which has a sensitivity
of 0.78 ng/ml and an intra-assay coefﬁ-
cient of variation (CV) of 1.8–6.2% for
adiponectin and a sensitivity of 0.5 ng/ml
and an intra-assay CV of 8.3% for leptin.
Plasma C-reactive protein (CRP) was
measured using the U.S. CRP ELISA Kit
(Diagnostic Systems Laboratories, Web-
ster, TX), with a CV range of 2.8–5.1%.
Soluble intercellular adhesion molecule
(sICAM)-1, soluble E-selectin (sE-
selectin), and soluble tumor necrosis fac-
tor (sTNF)-RII were assayed in plasma
using ELISA kits (R&D Systems, Minne-
apolis, MN) with CVs 8.8%.
Assessment of covariates
Data on demographic and lifestyle factors
were obtained from Nurses’ Health Study
questionnaires. BMI was calculated from
self-reported weight (in kg) in 1990 di-
vided by the square of height (in m
2)r e -
ported in 1976. Physical activity in
metabolic equivalent tasks (METs) per
week was computed from 1986 data on
duration and intensity of exercise per-
formed. Medication use and family his-
tory of diabetes were both assessed by the
1988 questionnaire. Smoking status and
status of self-reported hypertension and
hypercholesterolemiawereobtainedfrom
questionnairesadministeredin1990,and
race, marital status, education, and em-
ployment were addressed on the 1992
form. Alcohol and caffeine intake were
determined from the 1990 questionnaire
using a previously validated (12) semi-
quantitative food frequency question-
naire. Sleep duration was assessed by
questionnaire in 1986.
Statistical analyses
Comparisons of descriptive measures
were conducted using linear regression
for continuous variables and appropriate

2 tests for categorical variables across
groups of phobic anxiety (CCI 0–1, 2–3,
or 4). Associations of the CCI group
withbiomarkerconcentrationswereeval-
uatedusingsimplelinearregressionmod-
els for crude analysis and multiple linear
regression analysis to calculate adjusted
means, with logarithmic transformation
of outcome values to more closely ap-
proximate the normal distribution. We
adjusted for potential confounders in
multivariateanalyses,includingage,BMI,
employment status, education, marital
status, physical activity, smoking, hyper-
tensive status, hypercholesterolemia,
A1C concentration, family history of dia-
betes, sleep duration, and medication us-
age, with continuous variables categorized
in quintiles and modeled as four dichoto-
mous indicator variables in the multivar-
iate model. In a secondary analysis, we
also ran CCI as a continuous variable in a
model adjusting for BMI as a continuous
variable. Post hoc tests for differences be-
tween CCI groups were conducted using
Bonferroni adjustment for multiple com-
parisons within each variable (P value of
0.0125 was considered signiﬁcant on
posthoctest).Testsforinteractionbyage,
BMI, smoking status, alcohol consump-
tion, education, work status, marital sta-
tus, and duration of diabetes and the
relationship between phobic anxiety and
biochemical variables were conducted us-
ing linear regression with multiplicative in-
teractionterms.Thesetestswereconducted
for each biomarker separately. All analyses
were conducted using the SAS statistical
package(SASversion8.2forUNIX;SASIn-
stitute, Cary, NC). Reported P values are
two sided, and values 0.05 were used to
determine statistical signiﬁcance.
RESULTS— Descriptive characteris-
ticsof984womenwithtype2diabetesby
level of phobic anxiety are presented in
Table 1. Women with phobic anxiety
scores 4 had signiﬁcantly higher BMI
and were less highly educated than
women with scores of 3. These women
were also more likely to have a history of
hypertension and to smoke. With respect
to medical history, women with the high-
est phobic anxiety were more likely to
havebeendiagnosedwithdiabetesfor2
yearsandweremarginallylesslikelytobe
taking oral diabetes medications. Phobic
anxiety was also associated with use of
thiazidediuretics,calciumchannelblock-
ers, and other antihypertensive medica-
tions.Wefoundnosigniﬁcantdifferences
among varying levels of phobic anxiety in
age, energy intake and physical activity,
alcohol consumption, marital status, or
employment, nor did we detect signiﬁ-
cantdifferencesinothermedicalhistory
or other medication use (Table 1).
Women with high scores had signiﬁ-
cantlyelevatedconcentrationsofleptin,
sICAM-1, sTNF-RII, and a trend to-
ward elevated CRP concentrations (Ta-
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adiponectin.
Since there was no evidence of inter-
action by age (P  0.45–0.81), BMI (P 
0.09–0.91), smoking status (P  0.36–
0.92), alcohol consumption (P  0.06–
0.97), education (P  0.42–0.94), or
duration of diabetes (P  0.13–0.96) for
anyofthebiomarkers,crudeandadjusted
estimates of biomarkers by CCI group
from all subjects are presented (Table 2).
Adiponectin levels were not associated
with phobic anxiety in either crude or ad-
justed models or after mutual adjustment
for leptin. After controlling for age, BMI,
and race, the marginal association be-
tween CRP and phobic anxiety was atten-
uated to null and remained unassociated
with subsequent adjustments (Table 2).
sICAM-1 levels were also associated with
phobic anxiety in the crude analysis, but
theselostsigniﬁcanceafteradjustmentfor
age, BMI, and lifestyle factors (P  0.08).
Compared with the group with moderate
anxiety, sICAM-1 levels remained higher
in the group with higher anxiety in the
fully adjusted model. Similarly, sE-
selectin levels were signiﬁcantly higher in
the high-anxiety group compared with
the group with moderate anxiety before
and after adjustment for potential con-
founders, but the linear trend across ter-
tiles was nonsigniﬁcant (Table 2). For
each model, post hoc tests were con-
ducted using Bonferroni adjustments for
multiple comparisons, and comparisons
withaPvalueof0.012wereconsidered
signiﬁcant (Table 2). In the ﬁnal, fully ad-
justed model (model 3), mean leptin con-
centrations were signiﬁcantly higher for
women who scored 4 on the CCI com-
pared with both the ﬁrst (16% higher)
and second (13% higher) tertile of CCI
score. For sICAM-1, sE-selectin, and
sTNF-RII, signiﬁcant differences were
Table 1—Descriptive characteristics of women (n  984) with diabetes by category of CCI measuring phobic anxiety
CCI (0–16 points)
Ptrend 0o r1 2o r3 4
n 288 318 378
Demographic
Age (years) 59.3  6.5 58.8  6.7 58.5  6.7 0.13
BMI (kg/m
2) 29.9  6.4 29.2  6.1 30.6  6.4* 0.10
Physical activity (METs/week) 12.6  15.2 12.4  16.9 10.6  14.2 0.10
Total energy intake (kcal) 1,742  503 1,784  514 1,796  537 0.21
Alcohol (g/day) 3.0  7.4 2.7  6.6 2.8  8.6 0.68
Current smoker 29 (10.2) 47 (14.9) 60 (15.9) 0.04
Caucasian race 285 (98.9) 307 (96.5) 364 (96.3) 0.10
Married 228 (83.2) 249 (82.2) 294 (80.6) 0.38
Education (Bachelor’s degree) 88 (32.2) 70 (23.2) 71 (19.4) 0.0002
Full-time employment 82 (30.0) 76 (25.1) 98 (26.9) 0.43
Medical history
Hypertension 106 (36.8) 128 (40.3) 172 (45.5) 0.02
Hypercholesterolemia 123 (42.7) 119 (37.4) 153 (40.5) 0.63
Duration of diabetes 2 years 126 (43.8) 143 (45.0) 131 (34.7) 0.01
Family history of diabetes 149 (51.7) 164 (51.6) 198 (52.4) 0.86
Insulin 60 (20.8) 59 (18.6) 69 (18.3) 0.42
Oral diabetes medication 67 (23.3) 81 (25.5) 68 (18.0) 0.08
A1C (%) 7.0  1.8 6.9  1.7 6.8  1.7 0.12
Medications
Aspirin 133 (46.2) 146 (45.9) 158 (41.8) 0.24
Postmenopausal hormones 101 (35.1) 106 (33.3) 120 (31.8) 0.37
Thiazide diuretics 78 (27.1) 110 (35.6) 134 (35.5) 0.03
Other hypertension
medication 21 (7.3) 29 (9.1) 48 (12.7) 0.02
-Blocker 40 (13.9) 51 (16.0) 70 (18.5) 0.11
ACE inhibitor 25 (8.7) 23 (7.2) 44 (11.6) 0.16
Calcium channel blocker 6 (2.1) 21 (6.6) 24 (6.4) 0.02
Cholesterol-lowering
medication 17 (5.9) 15 (4.7) 13 (3.4) 0.13
Biomarkers
Adiponectin (g/ml) 5.3 (1.0–31.7) 6.1 (1.3–38.4) 5.4 (1.2–41.8) 0.35
Leptin (ng/ml) 44.0 (1.6–144) 40.1 (1.5–229) 47.7 (2.0–162)*† 0.006
CRP (mg/l) 3.5 (0.6–34) 3.4 (0.7–35) 3.9 (0.7–35) 0.06
sE-selectin (ng/ml) 59.0 (16.2–229) 55.9 (18.8–327) 61.0 (14.2–525)* 0.20
sICAM-1 (ng/dl) 290 (130–799) 285 (100–849) 305 (9.0–1,074)* 0.02
sTNF-RII (pg/ml) 2,387 (939–6,946) 2,310 (1,005–6,861) 2,496 (1,046–9,355)* 0.03
Data are means  SD, n (%), or median (range). *Signiﬁcantly different from group 2 (Bonferroni-adjusted P value 0.05). †Signiﬁcantly different from group 1
(Bonferroni-adjusted P value 0.05).
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andwomenwhoscored2or3ontheCCI
afterfulladjustment.sE-selectinwas11%
higher, sICAM-1 was 7% higher, and
sTNF-RIIwas5%higherinthethirdter-
tile compared with the second tertile of
CCI score. The associations of CCI 4
with increased leptin and sTNF-RII re-
mained signiﬁcant after adjusting for age,
BMI, and race.
To address the possibility of residual
confounding by BMI, we repeated the
analysistreatingBMIasacontinuousvari-
able. The results were not materially dif-
ferent from those presented (data not
shown). A total of 180 individuals in our
cohort had a score of 6 on the CCI;
theseindividualsaremorelikelytohavea
psychiatrist-diagnosed anxiety disorder
(11). When we separated these individu-
als out from the highest tertile and exam-
ined for a trend across groups, the
association between higher phobic anxi-
ety and higher leptin and aTNF-aRII per-
sisted(leptinPfortrend0.0006,sTNF-
aRII  0.004 in fully adjusted model).
Treating the CCI as a continuous variable
in the models yielded similar results to
those presented herein. Mutual adjust-
ment for leptin attenuated the associa-
tions between phobic anxiety and sTNF-
RII (P for trend  0.06), indicating that
variation in leptin levels may partly ex-
plain the association with sTNF-RII. In
contrast, leptin remained signiﬁcantly as-
sociated with the CCI, even after adjust-
ment for all other biomarkers.
CONCLUSIONS— We found that
higher levels of phobic anxiety, as mea-
suredbytheCCIin984womenwithtype
2diabetes,wereassociatedwithincreased
leptin and sTNF-RII measured within 2
years. Also, compared with women with
low or moderate phobic anxiety, women
with high levels of phobic anxiety had
higher sE-selectin and sICAM-1. In con-
trast, there was no association between
phobic anxiety and adiponectin levels.
The association between higher phobic
anxiety and higher leptin and sTNF-RII
remained signiﬁcant after adjustment for
BMI, lifestyle, and CVD risk factors in the
ﬁnal, fully adjusted model.
Elevations of inﬂammatory biomark-
ers (TNF- and CRP) have been associ-
ated with increased risk of CVD in
multiple prospective studies (13). In the
current study, we measured sTNF-RII,
the cleaved extracellular part of the cell
surfacereceptorforTNF-thatcorrelates
highly with TNF- and is less susceptible
to short-term variation. Inﬂammatory bi-
omarkers are increased in states of acute
psychological stress, and these results
have been extended to states of chronic
psychological distress, such as posttrau-
matic stress disorder (14). We demon-
strate that phobic anxiety is associated
with increased inﬂammatory biomarkers
and markers of endothelial dysfunction,
which may explain, in part, the associa-
tion between phobic anxiety and in-
creased CVD risk. Previous studies in
other groups, using other measures of
Table 2—Estimated crude (95% CI) and adjusted least-squares mean biomarker concentrations by CCI category for women (n  984) with
diabetes
CCI (0–16 points)
P trend 0o r1 2 – 3 4
n 288 318 378
Adiponectin (g/ml) 5.7 (5.3–6.2) 6.2 (5.7–6.7) 5.5 (5.1–5.9) 0.35
Model 1 5.4 5.7 5.3 0.68
Model 2 5.0 5.4 5.1 0.78
Model 3 6.0 6.6 6.4 0.34
Leptin (ng/ml) 34.7 (31.6–38.2) 33.1 (30.2–36.2) 40.9 (37.7–44.4)*† 0.006
Model 1 41.6 41.7 46.6 0.01
Model 2 37.0 38.1 43.3*† 0.002
Model 3 37.3 38.3 43.4*† 0.004
CRP (mg/l) 3.7 (3.3–4.1) 3.6 (3.2–3.9) 4.2 (3.8–4.6) 0.06
Model 1 4.1 4.1 4.5 0.11
Model 2 4.4 4.5 4.7 0.25
Model 3 4.4 4.5 4.7 0.38
sE-selectin (ng/ml) 59.0 (55.7–62.4) 55.1 (57.8–57.7) 61.5 (58.5–64.6)† 0.20
Model 1 61.2 57.6 63.4† 0.27
Model 2 61.4 57.6 63.1 0.40
Model 3 54.7 50.5 55.9† 0.43
sICAM-1 (ng/dl) 295 (284–306) 291 (281–302) 312 (302–322) † 0.02
Model 1 290 288 307*† 0.01
Model 2 325 318 340† 0.07
Model 3 311 303 325† 0.08
sTNF-RII (pg/ml) 2,397 (2,318–2,480) 2,382 (2,307–2,461) 2,516 (2,443–2,591)† 0.03
Model 1 2,481 2,490 2,611 0.02
Model 2 2,416 2,424 2,529 0.04
Model 3 2,487 2,495 2,629† 0.01
Model1:adjustedforage,BMI,andrace;model2:adjustedadditionallyforphysicalactivity,totalenergyintake,alcoholintake,smokingstatus,full-timeworkstatus,
educationlevel,andmaritalstatus;model3:adjustedadditionallyforhypertension,hypercholesterolemia,A1C,familyhistoryofdiabetes,aspirin,postmenopausal
hormone,insulin,oraldiabetesmedicationuse,sleepduration,anddurationofdiabetes.*Signiﬁcantlydifferentfromgroup1(Bonferroni-adjustedPvalue0.05).
†Signiﬁcantly different from group 2 (Bonferroni-adjusted P value 0.05).
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tion with inﬂammatory biomarkers, have
reported results consistent with those
presentedherein.Astudyofhealthyadult
men and women from Greece (7) found
that higher anxiety, as assessed by the
Spielberger State Anxiety Inventory, was
associated with higher CRP, interleu-
kin-6,homocystine,andﬁbrinogenlevels
in women, but this study did not adjust
for all potential confounding variables,
and only a small proportion of these
women had diabetes. We found only a
trend toward a signiﬁcant association be-
tween CRP and phobic anxiety in women
with diabetes (P  0.06 in crude analy-
sis), but this became nonsigniﬁcant after
adjustment for BMI, age, and race, indi-
cating that these variables may mediate
any association between phobic anxiety
and CRP. We did document signiﬁ-
cantly increased levels of sTNF-RII in
subjects with higher anxiety indicating
immune activation. This association be-
came nonsigniﬁcant after adjustment
for leptin, which may indicate an un-
derlying role for leptin, or overall fat
mass as expressed by leptin, to mediate
this association.
We have also documented increased
markersofendothelialactivation(i.e.,sE-
selectin and sICAM-1) in subjects with
higher anxiety. While the overall trend
across tertiles in a linear model was not
signiﬁcant, levels of sE-selectin and
sICAMwerehigherinwomenwithscores
of 4 compared with women with scores
of2or3.Thesecellularadhesionmarkers
have been associated with vascular dam-
age and are elevated in hypertension and
diabetes (15). Previous studies have dem-
onstrated increased expression of cell ad-
hesion molecules on leukocytes in
responsetostress,bothacuteandchronic
(16). To our knowledge, this is the ﬁrst
study to document increased circulating
vascular adhesion markers in a chronic
anxiety state independently of other con-
founding factors, and these data need to
be conﬁrmed by future studies.
We demonstrate herein that higher
phobic anxiety is associated with higher
circulatingleptinlevelsthatremainedsig-
niﬁcantafteradjustmentforpossiblecon-
founders and other biomarkers. In mice,
leptin is an important regulator of the hy-
pothalamic-pituitary-adrenal axis in re-
sponsetostress(17),buttheroleofleptin
in the response to chronic psychological
stress in humans is incompletely under-
stood. Although acute physical stress,
such as exposure to cold, results in a re-
duction in circulating leptin levels, acute
psychological stress has been associated
with increased leptin levels (18). In states
of chronic psychological stress, increased
leptin levels have also been described in
several studies, including a large cross-
sectional study in Japanese men that
found that higher perceived psychologi-
cal stress was associated with higher cir-
culating leptin levels (19) and a further
study documenting higher leptin levels in
subjects with posttraumatic stress disor-
der (20). Furthermore, in one study (21),
the increase in leptin levels in response to
acute stress was signiﬁcantly correlated
with waist circumference, but it remains
unclear whether increased waist circum-
ference is the cause or the effect. The re-
sults presented herein conﬁrm these
earlier studies by reporting signiﬁcantly
higherleptinlevelsinwomenwithhigher
phobic anxiety scores and may represent
an adaptive response to chronic stress ex-
posure, potentially resulting in chroni-
cally increased sympathetic nervous
system activation in these subjects. While
we adjusted for BMI in our analyses, we
were unable to adjust for overall fat mass,
whichisastrongerpredictorofleptinlev-
els and may underlie the association ob-
servedherein.Futurestudiesarerequired
to investigate whether higher fat mass
confounds this association and to deter-
mine whether leptin has any role in the
hypothalamic-pituitary-adrenal axis re-
sponse to stress in humans.
In contrast to leptin, we found no as-
sociation between phobic anxiety and
adiponectin, an adipocyte-secreted hor-
mone with an important role in insulin
resistance. Reduced adiponectin levels
have been associated with increased risk
of CVD in prospective cohort studies
(22), and increased sympathetic nervous
stimulation has been shown to reduce
adiponectin expression in cultured adi-
pocytes, and sympatholytic therapy in
humans is associated with increased se-
rum adiponectin (23,24). We know of no
other study that has examined the associ-
ation of phobic anxiety with adiponectin.
Althoughwehypothesizedthatadiponec-
tin might potentially mediate the associa-
tion between phobic anxiety, a condition
associated with increased activity of the
sympathetic nervous system, and CVD
risk, we did not observe any signiﬁcant
association either before or after adjust-
ment for demographic and lifestyle vari-
ables, indicating that this adipokine is
unlikely to be mechanistically involved in
any association between phobic anxiety
and CVD.
Our study has several strengths, in-
cluding its large sample size and prospec-
tive design, as well as the blinded
assessment of outcomes using state-of-the-
artmethodology.Potentiallimitationsalso
needtobeconsidered.Behavioralcharac-
teristics such as decreased physical activ-
ity and smoking may be on the causal
pathway of the association between pho-
bic anxiety and CVD risk markers. If this
was the case, then adjustment for these
covariates would have attenuated any as-
sociation between phobic anxiety and bi-
omarkers. Our study was limited to
women with diabetes, and whether these
ﬁndings apply to men or other groups of
patientsremainsunknown.Similartoany
observational study, a further limitation
of the study is the possibility for uncon-
trolled and/or residual confounding.
While we adjust for multiple possible
confounders such as sleep duration and
CVD risk factors in our analyses, other
unmeasured variables, such as fat mass,
may confound the observed relation-
ship. Random error in the measurement
of outcome variables may have resulted
in misclassiﬁcation, which could have
depressed effect estimates toward the
null but could not have accounted for
the statistically signiﬁcant results pre-
sented herein. Despite these potential
limitations, this is the ﬁrst study to assess
the association between many of the bi-
omarkers and adipokines reported
herein and phobic anxiety. These data
need to be conﬁrmed and extended in
future studies.
Insummary,ourﬁndingssuggestthat
the increased CVD risk in women with
phobic anxiety may be mediated in part
byanassociationwithelevatedinﬂamma-
tory biomarkers. The ﬁnding of elevated
adipokine levels in women with higher
levels of phobic anxiety may signify a role
for adipokines in the adaptation to a
chronic anxiety state and deserves further
study.
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